What is the BEAM stock price?

Beam Therapeutics Inc. (BEAM) last available close: $26.33, as of 11/3/26. Prices on Cylvex may be delayed.

How many analyst price targets for BEAM were reached?

3 of 12 published price targets for BEAM were reached within 12 months (25% reached); 6 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on BEAM?

14 firms have published price targets or ratings on BEAM that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

Updated Nov 3, 7:59 PM ET

BEAM

Beam Therapeutics Inc.

$26.41CS band Mixed

+$0.46 (1.78%) At close $26.33 · Today

☾After Hours +$0.08 (0.31%) Nov 3, 7:59 PM ET

About BEAM

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Cylvex Score

Mixed

Some risk factors elevated

Multi-factor score. Not a buy/sell signal.

Score history

Calibrating

Score history is calibrating — it appears once enough daily scores are recorded.

What goes into the score

6 axes · equal weight

AnalystWall Street consensus & target distance

GrowthEarnings growth trajectory

ProfitabilityROE, margins, cash generation

ValuationPE, PEG, price-to-book ratios

TechnicalsPrice momentum & 52-week position

RiskBeta, volatility, leverage

The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.